Business Description
Apellis Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
1JK.Germany
•
APLS.USA
Description
Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3 the central protein in the complement cascade.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.04 | |||||
| Equity-to-Asset | 0.33 | |||||
| Debt-to-Equity | 0.63 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.09 | |||||
| Beneish M-Score | 20.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -55.6 | |||||
| 3-Year EPS without NRI Growth Rate | -55.7 | |||||
| 3-Year FCF Growth Rate | -40.4 | |||||
| 3-Year Book Growth Rate | -10.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.01 | |||||
| 9-Day RSI | 44.88 | |||||
| 14-Day RSI | 47.2 | |||||
| 6-1 Month Momentum % | 14.02 | |||||
| 12-1 Month Momentum % | 86.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.57 | |||||
| Quick Ratio | 7.19 | |||||
| Cash Ratio | 6.73 | |||||
| Days Inventory | 1151.58 | |||||
| Days Sales Outstanding | 21.3 | |||||
| Days Payable | 623.05 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.1 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 93.24 | |||||
| Operating Margin % | -512.22 | |||||
| Net Margin % | -660.59 | |||||
| ROE % | -400.76 | |||||
| ROA % | -75.01 | |||||
| ROIC % | -755.01 | |||||
| ROC (Joel Greenblatt) % | -2004.28 | |||||
| ROCE % | -84.81 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 59.83 | |||||
| PB Ratio | 19.5 | |||||
| Price-to-Tangible-Book | 19.5 | |||||
| EV-to-EBIT | -9.87 | |||||
| EV-to-Forward-EBIT | -11.92 | |||||
| EV-to-EBITDA | -9.89 | |||||
| EV-to-Forward-EBITDA | -12.12 | |||||
| EV-to-Revenue | 62.75 | |||||
| EV-to-Forward-Revenue | 29.27 | |||||
| EV-to-FCF | -13.71 | |||||
| Price-to-Net-Current-Asset-Value | 22.36 | |||||
| Price-to-Net-Cash | 35.28 | |||||
| Earnings Yield (Greenblatt) % | -10.12 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:APLS
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 96.643 | ||
| EPS (TTM) ($) | -6.69 | ||
| Beta | 1.8 | ||
| Volatility % | 54.08 | ||
| 14-Day RSI | 47.2 | ||
| 14-Day ATR ($) | 4.211297 | ||
| 20-Day SMA ($) | 63.657 | ||
| 12-1 Month Momentum % | 86.63 | ||
| 52-Week Range ($) | 30.1707 - 70 | ||
| Shares Outstanding (Mil) | 109.87 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Apellis Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Apellis Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.